By Gilang Cahya 
A significant advancement in the diagnostic landscape of Alzheimer’s disease has emerged from the LMU University Hospital in Munich, Germany. A dedicated research group has meticulously investigated and refined methods for the more reliable and cost-effective detection of amyloid plaques, a key pathological hallmark of the neurodegenerative condition. This work is poised to directly influence patient care as the first generation of disease-modifying Alzheimer’s drugs, targeting these very plaques, gain regulatory approval and become accessible.
The European Medicines Agency (EMA) granted approval for Lecanemab in the European Union on November 14, 2024. This milestone signifies a new era in Alzheimer’s treatment, offering hope to patients and clinicians alike. These groundbreaking drugs operate by targeting and clearing the abnormal amyloid plaques that accumulate in the brain, disrupting neuronal function and contributing to cognitive decline. However, the efficacy of these therapies hinges on their timely and accurate administration to the appropriate patient population. The crucial question facing the medical community is how to reliably and cost-effectively identify individuals with these amyloid plaques, particularly those presenting with early signs of cognitive impairment or mild dementia – the primary target group for these novel treatments.
Addressing this critical need, a comprehensive study conducted by leading clinicians at LMU University Hospital offers vital insights that are expected to be integrated into current patient management strategies. The research initiative was spearheaded by Professor Matthias Brendel, Acting Director of the Department of Nuclear Medicine, Dr. Nicolai Franzmeier from the Institute for Stroke and Dementia Research, and Professor Günther Höglinger, Director of the Neurological Clinic. All three researchers are also distinguished members of the SyNergy Cluster of Excellence, underscoring the collaborative and high-caliber nature of this investigation. The impactful findings of this study have now been formally published in the prestigious journal Alzheimer’s & Dementia: Diagnosis, Assessment, & Disease Monitoring, a publication of the Alzheimer’s Association.
Evaluating Diagnostic Methodologies: A Comparative Analysis
At present, two primary methods are approved for the definitive identification of amyloid plaques in the brains of individuals suspected of having Alzheimer’s disease. The first, known as cerebrospinal fluid (CSF) analysis, involves the extraction of fluid from the spinal canal.
Method 1: Cerebrospinal Fluid (CSF) Analysis
This method requires a lumbar puncture, commonly referred to as a spinal tap, which necessitates the insertion of a needle into the lower back. While a generally safe procedure, it is invasive and carries a small risk of complications. Furthermore, CSF analysis is not suitable for all patients, particularly those on anticoagulant therapy due to an increased risk of bleeding. Critically, CSF analysis provides indirect evidence of amyloid deposits. It measures the levels of specific amyloid-beta proteins in the CSF, where lower levels can indicate the presence of plaques in the brain as the proteins are being sequestered by these deposits. However, this method is non-quantitative, meaning it does not provide a precise measurement of the plaque burden.
Method 2: Positron Emission Tomography (PET) Imaging
The second established method is positron emission tomography (PET) scanning, a non-invasive brain imaging technique. PET scans utilize a radioactive tracer that binds to amyloid plaques, allowing for their visualization and quantification directly within the brain. This method offers direct, semiquantitative evidence of amyloid deposits. However, the current cost of an amyloid PET scan, ranging from approximately 1,500 to 3,000 euros per scan, remains a significant barrier to widespread adoption. These costs are often not covered by standard health insurance plans in Germany, limiting its accessibility. Moreover, the availability and utilization of amyloid PET and CSF analysis vary across different healthcare centers in Germany, with CSF analysis currently being the more frequently employed diagnostic tool due to its broader accessibility and lower cost, despite its limitations.
The Munich-based research team embarked on a rigorous study to systematically compare the diagnostic accuracy of CSF tests against the established gold standard of amyloid PET imaging. To achieve this, they meticulously evaluated the clinical data of over 400 patients who had undergone both a CSF amyloid test and an amyloid PET scan at LMU University Hospital between 2013 and 2024. These patients were all presenting with suspected Alzheimer’s disease, underscoring the clinical relevance of the study’s findings.
Robust Findings and the "Gray Area" of Diagnosis
The analysis of this extensive dataset yielded compelling results that shed new light on the diagnostic capabilities of both methods. A key finding emerged concerning specific amyloid levels within the CSF. Patients exhibiting amyloid values exceeding 7.1 in their CSF tests were overwhelmingly found to have normal PET scans, indicating a negative result for Alzheimer’s disease. Conversely, individuals with CSF amyloid values below 5.5 predominantly showed abnormal findings on their PET scans, strongly suggesting the presence of Alzheimer’s disease with a high degree of probability.
However, the study identified a critical "gray area" within the CSF results, ranging from 5.5 to 7.1. This intermediate range encompassed approximately 15 to 20 percent of the study participants. Within this ambiguous zone, the diagnostic concordance between CSF and PET significantly diminished. "Half of these study participants had abnormal amyloid results in their PET scans," stated Professor Brendel, highlighting the inherent unreliability of CSF analysis in this particular range. "And so the CSF is not reliable enough here."
To ensure the robustness and generalizability of these findings, the researchers replicated their analysis on an independent cohort of patients at the University of Vienna. The outcomes from the Vienna cohort mirrored those observed in Munich, providing strong validation for the study’s conclusions. This independent confirmation significantly enhances the credibility and impact of the research, suggesting that these findings are not specific to the LMU cohort but are likely representative of a broader patient population.
Implications for Clinical Practice and Future Pathways
The implications of this study are profound, particularly as the new amyloid-targeting drugs gain traction in clinical practice. The research provides a clear roadmap for optimizing diagnostic pathways and ensuring that patients receive the most appropriate and timely assessment.
A Tiered Diagnostic Approach
Professor Brendel outlined a proposed strategy for integrating these findings into clinical decision-making. "As soon as the new drugs for treating amyloid plaques are approved, the findings of the study could be incorporated into diagnostic practice," he explained. "Amyloid PET would be the diagnostic method of choice where available."
However, acknowledging the current disparities in access and infrastructure across Germany, the researchers propose a pragmatic, tiered approach. "Depending on the expertise and equipment at a given location, however, many patients in Germany currently have readier access to CSF analysis than to amyloid PET," Professor Brendel noted. "From medical and economic standpoints, therefore, it seems reasonable to give these patients a CSF analysis in the first instance unless there are specific medical reasons to indicate otherwise."
This initial CSF analysis would serve as a screening tool for the majority of patients. This approach is estimated to be relevant for approximately 70 to 80 percent of individuals presenting with mild cognitive impairment or dementia.
Targeted Use of Amyloid PET
Crucially, the study’s findings identify a specific subgroup of patients who would benefit most from a subsequent amyloid PET scan. "Of these patients, only those whose results are in the gray area between 5.5 and 7.1 would then need an additional PET scan," Professor Brendel elaborated. This targeted approach aims to avoid unnecessary PET scans for patients who are clearly positive or negative based on their CSF results, thereby optimizing resource allocation and reducing patient burden.
The research team also anticipates a future where the cost and accessibility of amyloid PET scans improve. "Especially if the costs of amyloid PET fall in future and broader access becomes possible, amyloid PET could become the first choice and avoid the duplication of effort and costs involved where two tests — CSF and PET — are currently required," Professor Brendel concluded. This forward-looking perspective suggests that as technology advances and healthcare policies evolve, amyloid PET imaging may eventually supersede CSF analysis as the primary diagnostic modality for amyloid plaque detection.
Broader Context and Future Directions
The development of disease-modifying therapies for Alzheimer’s disease has been a long and arduous journey, marked by numerous setbacks and the pursuit of various therapeutic targets. For decades, researchers have focused on understanding the complex pathological processes underlying the disease, with amyloid-beta plaques and tau tangles emerging as central players. The approval of drugs like Lecanemab represents a significant breakthrough, shifting the paradigm from purely symptomatic treatment to interventions that can potentially alter the course of the disease.
However, the effectiveness of these therapies is intrinsically linked to their ability to target the disease in its early stages, when amyloid plaques are present but before widespread neuronal damage has occurred. This underscores the critical importance of accurate and timely diagnosis. The LMU study directly addresses this need by providing empirical evidence to refine diagnostic protocols.
The research also highlights the ongoing challenge of balancing diagnostic accuracy with healthcare costs and accessibility. While PET imaging offers superior direct visualization and quantification of amyloid plaques, its high cost remains a significant hurdle in many healthcare systems. The proposed tiered approach, leveraging the accessibility of CSF analysis as an initial screening tool, represents a pragmatic solution that maximizes diagnostic yield while managing resources effectively.
Looking ahead, several factors could further influence the adoption of these findings. Continued research into the cost-effectiveness of amyloid PET imaging and the development of more affordable tracers could pave the way for broader utilization. Furthermore, evolving reimbursement policies from health insurance providers will play a crucial role in determining the accessibility of PET scans for patients.
The collaborative efforts of institutions like LMU University Hospital and the SyNergy Cluster of Excellence are vital in pushing the boundaries of Alzheimer’s research. By providing clear, evidence-based guidance on diagnostic methodologies, these researchers are not only advancing scientific knowledge but also equipping clinicians with the tools necessary to provide optimal care for individuals living with or at risk of Alzheimer’s disease, especially as the landscape of treatment options continues to expand. The successful integration of these refined diagnostic strategies will be instrumental in unlocking the full potential of new Alzheimer’s therapies and improving the lives of countless patients worldwide.